Actively Recruiting
Comparing Carbetocin and Oxytocin to Prevent Heavy Bleeding After Cesarean Delivery in Women at High Risk
Led by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Updated on 2026-04-01
160
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying postpartum hemorrhage PPH, a serious bleeding complication after cesarean delivery CD, focusing on patients at higher risk for this condition. The study compares two drugs commonly used to prevent excess uterine bleeding oxytocin and carbetocin. Carbetocin, a synthetic oxytocin analog, has a longer-lasting effect and may reduce the need for continuous infusion compared to oxytocin. The trial aims to provide evidence on their relative effectiveness and safety in high-risk patients, which could guide future treatment guidelines. Participants will be randomly assigned to receive either oxytocin or carbetocin during elective cesarean delivery. Oxytocin is given as a 5 IU intravenous dose over 1 minute followed by continuous infusion for 4 hours, while carbetocin is administered as a 100 mcg intravenous dose over 1 minute followed by a placebo infusion. Both treatments are designed to prevent uterine atony and reduce bleeding after childbirth. During the study, researchers will monitor the need for additional uterotonic agents within 90 minutes after delivery as the primary outcome. Secondary assessments include uterine tone at different time points, blood loss measurements, and various safety parameters such as blood pressure, heart rate, and symptoms like nausea or chest pain. Participants will be observed for up to 24 hours post-delivery to evaluate recovery and any complications related to bleeding or treatment. The total duration of participation covers the immediate period around the cesarean delivery and the following day.
CONDITIONS
Brief Title
Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery
Research Team
M
Mrinalini Balki, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here